@article{ccd8e52d6f9544869aee9edeadb729a5,
title = "American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation",
abstract = "The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed and answered FAQs. Topics were finalized with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. The third topic in the series focuses on the prevention of cytomegalovirus infection and disease in HCT recipients by reviewing prophylaxis and preemptive therapy approaches; key definitions, relevant risk factors, and diagnostic monitoring considerations are also reviewed.",
keywords = "Cytomegalovirus, Guideline, Hematopoietic cell transplant, Preemptive therapy, Prevention, Prophylaxis",
author = "Morgan Hakki and Aitken, {Samuel L.} and Lara Danziger-Isakov and Michaels, {Marian G.} and Carpenter, {Paul A.} and Chemaly, {Roy F.} and Papanicolaou, {Genovefa A.} and Michael Boeckh and Marty, {Francisco M.}",
note = "Funding Information: Conflict of interest statement: L.D-I. Has served as a consultant for Merck and Takeda, and has contracted clinical trial support provided to institution from Ansun BioPharma, Astellas, Merck, Takeda/Shire and Viracor. M.G.M. Contracted clinical trial support provided to institution from Viracor. R.F.C. Research Grants from Gilead, Pulmotec, Janssen, Karius, Chimerix, Merck, Viracor, Takeda/Shire, and Ansun Pharmaceuticals. Advisory Board/Consultant: ADMA Biologics, Pulmotec, Ablynx, Janssen, Merck, ReViral, Kyorin, Chimerix, Partner Therapeutics, Takeda, Adagio Therapeutics, and Ansun Pharmaceuticals. G.A.P. has served as an investigator and received research grant support from Chimerix, Astellas Pharma, Merck & Co, and Shire/Takeda and has received consulting/other fees from Chimerix, Inc, Astellas, Merck& Co, Cidara, Amplyx, AlloVir, Shionogi, Partners Therapeutics, ADMA Biologics and Siemens Healthineers. M.B. Research Grants: Merck & Co, Shire/Takeda, Astellas, Gilead; Consulting fees: Merck & Co, Shire/Takeda, Gilead, Glaxo Smith Kline, AlloVir, Moderna, Symbio, Vir Bio; Advisory Board with options to acquire equity Helocyte, Evrys Bio. F.M.M. Research grants from Amplyx, Ansun, Chimerix, Cidara, F2G, Gilead, Merck, Regeneron, Scynexis, Takeda, WHISCON; Honoraria from AlloVir, Amplyx, Avir, F2G, Gilead, Kyorin, Merck, Regeneron, ReViral, Symbio, United Medical. Funding Information: The authors thank Angie Dahl and Jessica Scott of American Society for Transplantation and Cellular Therapy for administrative support. These guidelines are dedicated to the memory of Dr. Francisco Marty, whose passion for the field of Transplant Infectious Diseases was an inspiration to us all. Financial disclosure: None. Conflict of interest statement: L.D-I. Has served as a consultant for Merck and Takeda, and has contracted clinical trial support provided to institution from Ansun BioPharma, Astellas, Merck, Takeda/Shire and Viracor. M.G.M. Contracted clinical trial support provided to institution from Viracor. R.F.C. Research Grants from Gilead, Pulmotec, Janssen, Karius, Chimerix, Merck, Viracor, Takeda/Shire, and Ansun Pharmaceuticals. Advisory Board/Consultant: ADMA Biologics, Pulmotec, Ablynx, Janssen, Merck, ReViral, Kyorin, Chimerix, Partner Therapeutics, Takeda, Adagio Therapeutics, and Ansun Pharmaceuticals. G.A.P. has served as an investigator and received research grant support from Chimerix, Astellas Pharma, Merck & Co, and Shire/Takeda and has received consulting/other fees from Chimerix, Inc, Astellas, Merck& Co, Cidara, Amplyx, AlloVir, Shionogi, Partners Therapeutics, ADMA Biologics and Siemens Healthineers. M.B. Research Grants: Merck & Co, Shire/Takeda, Astellas, Gilead; Consulting fees: Merck & Co, Shire/Takeda, Gilead, Glaxo Smith Kline, AlloVir, Moderna, Symbio, Vir Bio; Advisory Board with options to acquire equity Helocyte, Evrys Bio. F.M.M. Research grants from Amplyx, Ansun, Chimerix, Cidara, F2G, Gilead, Merck, Regeneron, Scynexis, Takeda, WHISCON; Honoraria from AlloVir, Amplyx, Avir, F2G, Gilead, Kyorin, Merck, Regeneron, ReViral, Symbio, United Medical. Authorship statement: •••. Publisher Copyright: {\textcopyright} 2021 The American Society for Transplantation and Cellular Therapy",
year = "2021",
month = sep,
doi = "10.1016/j.jtct.2021.05.001",
language = "English (US)",
volume = "27",
pages = "707--719",
journal = "Transplantation and Cellular Therapy",
issn = "2666-6375",
publisher = "Elsevier BV",
number = "9",
}